title: A study of reported factor IX use around the world.
abstract: Replacement therapy has significantly improved the life expectancy and lifestyle of people with haemophilia. The objectives of this article were to study the reported factor IX (FIX) use on a country-by-country basis and address the following question: Does the reported FIX use vary by national economies? We obtained data on the reported number of international units (IUs) of FIX used for 90 countries from the Marketing Research Bureau and the World Federation of Hemophilia. Results show that the reported FIX use varies considerably across national economies, even among the wealthiest of countries.Trends suggest that the reported FIX usage increases with increasing economic capacity and has been increasing over time. Trends also suggest that consumption of FIX has been increasing at a greater rate in high income countries. Given these trends, there will likely be an overall increase in the amount of FIX concentrates used in the treatment of haemophilia B. We also found that FIX use both in terms of IUs per capita and IUs per person provide a complete picture of the level of haemophilia care within a country. Such information is critical for planning efforts of national healthcare agencies to determine realistic budget priorities and pharmaceutical manufacturers to determine adequate production levels of FIX concentrates. By improving the data collection and surveillance of FIX use for the treatment of people with haemophilia B, we can identify trends and needs of patients and highlight best treatment practices among countries.
authors.affiliation: North Carolina State University, College of Management, Raleigh, NC 27695-7229, USA. jeff_stonebraker@ncsu.edu
authors.forename: J S
authors.initials: JS
authors.lastname: Stonebraker
authors.forename: P H B
authors.initials: PH
authors.lastname: Bolton-Maggs
authors.forename: M
authors.initials: M
authors.lastname: Brooker
authors.forename: A
authors.initials: A
authors.lastname: Farrugia
authors.forename: A
authors.initials: A
authors.lastname: Srivastava
mesh_terms: D003695:Delivery of Health Care; D019049:Developed Countries / Q000191:economics*; D003906:Developing Countries / Q000191:economics*; D004363:Drug Utilization; D005164:Factor IX / Q000627:therapeutic use*; D014943:Global Health; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D007182:Income
chemical_list: D005164:Factor IX